Trial
NCT05403723
Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC
Phase ISUSPENDEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Maryland, Baltimore
Collaborators
AstraZeneca
Condition
Extensive-stage Small-cell Lung Cancer
Intervention
Durvalumab 50 MG/1 ML Intravenous Solution
Why stopped
PI changed institution. Not yet approved at current location.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-02-19